Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Administration supports patent reform bill

This article was originally published in The Gray Sheet

Executive Summary

Efforts to revamp the U.S. patent system this year may have received a boost last week, when the Obama administration penned a letter generally supportive of a Senate bill (S. 515) that passed through the Judiciary Committee in April (1"The Gray Sheet" April 6, 2009). S. 515 is an important step "in placing the U.S. Patent and Trademark Office (USPTO) on a sound financial footing and ensuring that the intellectual property system as a whole is in a strong position to further our economic recovery," Commerce Secretary Gary Locke writes in an Oct. 5 2letter to the Senate committee. Judiciary Chairman Patrick Leahy, D-Vt., suggested in response to the letter he would work with the Senate leadership to move the bill to floor debate this year. Secretary Locke specifically endorsed the compromise fashioned in Leahy's committee to adjust the way infringement damages are calculated using the so-called "gatekeeper" approach. He requests some adjustments to the bill, however, regarding the scope of prior art and a grace period

You may also be interested in...



Senate Panel Passes Patent Bill; Floor Fight Expected

The Senate Judiciary Committee April 2 approved comprehensive patent reform legislation by a 15-4 vote after reaching nearly unanimous agreement on formerly contentious damages provisions

Scrip M&A Podcast: Which Companies Could Be Acquired Next?

The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel